Please login to the form below

Not currently logged in
Email:
Password:

gastric cancer

This page shows the latest gastric cancer news and features for those working in and with pharma, biotech and healthcare.

Pfizer gets first FDA nod for hedgehog inhibitor in AML

Pfizer gets first FDA nod for hedgehog inhibitor in AML

The small-molecule drug blocks part of the Sonic hedgehog pathway, which is also targeted by other cancer drugs including Roche’s Erivedge (vismodegib) and Novartis’ Odomzo (sonidegib) for basal cell ... Erivedge has been discontinued for AML and

Latest news

  • Roche builds on Immunocore ImmTAC deal Roche builds on Immunocore ImmTAC deal

    The trial is scheduled to start in early 2019, and will include a host of cancers, including non-small cell lung cancer (NSCLC), bladder cancer, head and neck cancer, gastric cancer ... Those molecules are based on soluble, engineered TCR’s, which

  • Home-grown colorectal cancer drug approved in China Home-grown colorectal cancer drug approved in China

    China looks set to be a big market for the drug in its own right, however, as CRC is the second-most common form of cancer with an estimated 380, 000 ... alongside AZ’s EGFR inhibitor Iressa (gefitinib), as well as gastric cancer.

  • China’s BeiGene raises $903m from Hong Kong IPO China’s BeiGene raises $903m from Hong Kong IPO

    cancer (NSCLC), hepatocellular carcinoma, and oesophageal squamous cell carcinoma, the company is developing BTK inhibitor zanubrutinib and pamiparib, a PARP 1/2 inhibitor. ... Meanwhile, pamiparib is being developed for solid tumours, and last month

  • Immuno-oncology at ASCO: survival data, combinations and new indications Immuno-oncology at ASCO: survival data, combinations and new indications

    have an impact on the fortunes of established and emerging cancer drugs and their developers. ... in small-cell lung cancer, gastric or gastroesophageal junction (G/GEJ) cancer and Merkel cell carcinoma.

  • ViiV’s two-drug HIV combo backed by CHMP ViiV’s two-drug HIV combo backed by CHMP

    CHMP meeting round-up. Among other highlights the CHMP backed two biosimilar medicines - Amgen’s Kanjinti version of Roche’s Herceptin (trastuzumab) for the treatment of breast and gastric cancer and ... It also gave its blessing to Clovis

More from news
Approximately 3 fully matching, plus 63 partially matching documents found.

Latest Intelligence

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    13 new targeted medicines that block the growth and spread of cancer by interfering with specific molecular targets. ... The field is marching on rapidly. Studies of checkpoint inhibitors are now taking place in less common forms of cancer with greater

  • Astellas: Ten years young Astellas: Ten years young

    There it is currently conducting a series of investigations in breast cancer to assess Xtandi's potential. ... It's not all been plain sailing for Astellas in oncology - a couple of candidates, notably rilotumumab, have fallen by the wayside in gastric

  • Deal Watch table for October 2014 Deal Watch table for October 2014

    1, 000. Aduro BioTech/J&J. Expansion of collaboration. Lung cancer immunotherapies including ADU 214. ... 525. F-star Alpha/BMS. Option to acquire F-star Alpha. Includes FS102 a P1 ready treatment for HER2 positive patients with breast /   gastric

  • Pharma deals during October 2014 Pharma deals during October 2014

    Now with a headline of $847m, Aduro receives an upfront of $30m with $817m in milestones for ADU 214 in the treatment of lung cancer. ... access to its lead candidate FS102 for HER-2 positive patients in breast and gastric cancer.

  • Deal Watch table for January 2014 Deal Watch table for January 2014

    100. Cancer Prevention Pharmaceuticals/ Zeria Tillotts Pharma. Exclusive licensing agreement for Europe and Japan. ... 100+. ACT Biotech/ Eddingpharm. Acquisition. Acquisition of 3 small molecule assets: Telatinib, a p3 ready VEGFr inhibitor for gastric

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Healthcircle

We're Healthcircle – an award-winning healthcare advertising and creative communications agency, offering a holistic approach to brand health. With a...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics